TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04092764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks. The acupoints will be stimulated by the electroacupuncture machine with alternating frequencies in order to induce endorphins at different points in the nervous system. Frequencies between 2 Hz and 100 Hz will be utilized. Sterile single-use needles will be placed at Ba Feng, four points on the dorsum of each foot between the digits. KI2 (Rang Gu), a point located at the soles of the feet and SP-4 (Gongsun) will also be needled per recommendation of our acupuncturist. A total of 12 needles will be used per participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroMetrix
Description: The NeuroMetrix is a point-of-care conduction device that will be used to measure peripheral neuropathy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rydel-Seiffer tuning fork
Description: The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight. This test will be performed three times and a mean of the scores calculated. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN
Study: NCT01125748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma therapies
Description: Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma therapies
Description: Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
Study: NCT02875080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Study: NCT04042363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transorbital electrical stimulation (Eyetronic Next Wave 1.1)
Description: Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous.~Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation
Description: The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will manually interrupt the stimulation 60 seconds after the start of the session.
Study: NCT00654030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1650-G Vaccine
Description: .6ml injection administered intradermally in the thigh at week 0 and week 4
Study: NCT02193165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
Description: Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
Study: NCT03579537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradyalisis without exercise programe
Description: patients on hemodialysis are evaluated with all the variables at first (T1) and without intervening in the treatment for 3 months they are evaluated again (T2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradyalisis with exercise programe
Description: After 3 first month without intervention and also during the time of hemodialysis, the patients star the exercise programe, the first part of the session, an exercise was carried out for cardiovascular work (pedaling on ergometer) and muscle toning, with special attention to the muscular development of the lower limbs (exercises with elastic bands and / or weighted ankles). The session increased in duration and intensity as the physical action program progressed throughout the duration of the permitted period (3 months) and always attending to the individual needs of each subject. In addition, each of the participants will be given a series of recommendations of exercise practice to be carried out during non-hemodialysis days, in order to complement the work done during the sessions.3 month later the investigator evaluated all the variable again (T3)
Study: NCT02468453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: velos
Description: VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: velos
Description: VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: velos
Description: VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: velos
Description: VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
Study: NCT04203056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil
Description: 12 month longitudinal aripiprazole lauroxil treatment and assessment follow-through

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARI-ORAL
Description: oral aripiprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-NCD
Description: Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release
Study: NCT01717508

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: 12 sessions of cognitive behavioral therapy
Study: NCT04073550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Anlotinib blank analog capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: A topoisomerase I inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan
Description: A topoisomerase I inhibitor.
Study: NCT02363179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live preferential music
Description: Live preferential music will be performed for patients in the emergency department.
Study: NCT00921869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
Study: NCT02207114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Algorithm Intervention
Description: The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
Study: NCT04515355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready for MS
Description: Receive 'ready for MS' programme in addition to standard care.
Study: NCT03007264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma
Description: CAP will be applied on one volar arm of volunteers for a total of 2 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma
Description: CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
Study: NCT01856101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
Study: NCT03510793

Intervention type: DRUG
Intervention: balanced anesthesia
Description: patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia

Intervention type: DRUG
Intervention: Total intravenous anesthesia
Description: patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
Study: NCT00619229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil (prostaglandin E1)
Description: Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo/d i.v. for 15 days
Study: NCT02065089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: playing the ipad quiz game
Description: Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
Study: NCT03714126

Intervention type: DEVICE
Intervention: Cordio Medical
Description: Recording to an app, no interference to the regular care
Study: NCT01103739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04531083
Description: PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04531083
Description: PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
Study: NCT02193165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
Description: Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoride toothpaste + fluoride Mouthwash
Description: Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
Study: NCT04264130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-Pyronaridine
Description: Subjects received artesunate-pyronaridine according to their body weight once per day for three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine
Description: subjects received artemether-lumefantrine according to their body weight twice per day for three days.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Artefenomel-Ferroquine
Description: Subject received a single dose of artefenomel-ferroquine according to their body weight
Study: NCT02959268

Intervention type: DEVICE
Group type: OTHER
Intervention: Al-Sense
Description: Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
Study: NCT03399084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: 750 mg/15 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: 750 mg/15 mL
Study: NCT01634594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group R
Study: NCT01103739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
Study: NCT01634594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group N

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group D
Study: NCT02730559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing/Counselling
Description: Motivational Interviewing/Counselling
Study: NCT01732900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morphology
Description: Embryos selected for transfer will be based upon morphology alone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GemART assay
Description: Embryos selected for transfer will be based upon morphology and GemART assay.
Study: NCT00923312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9201
Description: CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
Study: NCT01320449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin
Description: rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin
Description: rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
Study: NCT02193152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT00303797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study: NCT03402412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: narrow-band UVB
Description: Standard established treatment for atopic dermatitis with narrow-band UVB will be used in this study but initially only on a small amount of skin to assess what changes takes place in the skin.
Study: NCT04230070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug
Description: Bioequivalence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product
Description: Bioequivalence
Study: NCT02257151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02939664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Banded (with polypropylene mesh) gastric bypass
Description: The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: In this case a simplified conventional gastric bypass will be performed
Study: NCT02756468

Intervention type: OTHER
Intervention: pts operated for pancreatic cancer
Description: measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
Study: NCT01922193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Purified Urofollitropin
Description: for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Follitropin Alfa
Description: for injection
Study: NCT02713620

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)
Description: Different HBV vaccine regimen in each group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)
Description: Different HBV vaccine regimen in each group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)
Description: Different HBV vaccine regimen in each group

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)
Description: Different HBV vaccine regimen in each group
Study: NCT02702856

Intervention type: OTHER
Intervention: ExoIntelliScore Prostate
Study: NCT00004055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT01626313

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS Individualized Family Resiliency Training
Description: Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS Individualized Family Resiliency Training
Description: Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
Study: NCT04726904

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sacral neuromodulation in conventional implantation technique
Description: Sacral neuromodulation is implanted with the patients in a prone position, then the insert point of the needle is decided according to anatomical landmarks; afterwards, the lead will be inserted.
Study: NCT03837938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levopront® syrup 30 mg/5 ml
Description: The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Libexin®
Description: The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
Study: NCT02100709

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiLevel Noninvasive Ventilation
Description: Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
Study: NCT03442400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
Description: We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.
Study: NCT02730559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Counselling
Description: Motivational Interviewing/Counselling
Study: NCT01120639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)